Male Contraception: Where are we going and where have we been?

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Progress in developing new reversible male contraception has been slow. While the hormonal approach has been clearly shown to be capable of providing effective and reversible contraception, there remains no product available. Currently, trials of a self-administered gel combination of testosterone and the progestogen Nestorone® are under way, complementing the largely injectable methods previously investigated. Novel long-acting steroids with both androgenic and progestogenic activity are also in early clinical trials. The non-hormonal approach offers potential advantages, with potential sites of action on spermatogenesis, and sperm maturation in the epididymis or at the vas, but remains in preclinical testing. Surveys indicate the willingness of men, and their partners, to use a new male method, but they continue to lack that opportunity.
Original languageEnglish
Pages (from-to)236-242
Number of pages8
JournalBMJ Sexual & Reproductive Health
Issue number4
Early online date19 Sept 2019
Publication statusPublished - 15 Oct 2019


Dive into the research topics of 'Male Contraception: Where are we going and where have we been?'. Together they form a unique fingerprint.

Cite this